Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy

Journal of Nuclear Medicine

Volumn 56, Issue 8, 2015, Pages 1185-1190

  Morigi, Joshua J ^a,b   Stricker, Phillip D ^c,d   Van Leeuwen, Pim J ^c,d   Tang, Reuben ^a,e   Ho, Bao ^a   Nguyen, Quoc ^c,d   Hruby, George ^f   Fogarty, Gerald ^c   Jagavkar, Raj ^c   Kneebone, Andrew ^f   Hickey, Adam ^a   Fanti, Stefano ^b   Tarlinton, Lisa ^a   Emmett, Louise ^a,e  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c ST VINCENT'S CLINIC   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

68Ga PSMA; 18F fluoromethylcholine; Molecular imaging; PET CT; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

FLUOROMETHYLCHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; FLUOROMETHYLCHOLINE; GALLIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FALSE POSITIVE RESULT; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MALE; MOLECULARLY TARGETED THERAPY; PET-CT SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; VERY ELDERLY; ANALOGS AND DERIVATIVES; BIOPSY; BLOOD; CHEMISTRY; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; IMAGE PROCESSING; LABORATORY DIAGNOSIS; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSTATIC NEOPLASMS; SALVAGE THERAPY; SCINTISCANNING; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; BIOPSY; CHOLINE; FALSE POSITIVE REACTIONS; GALLIUM RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84938899767     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.160382     Document Type: Article

References (23)

1. Schwarz R, Graefen M, Krüll A. Therapy of treatment failure after curative treatment of prostate cancer. EAU-EBU Update Series 4. 2006;4:228-240.
2. Ménard C, Iupati D, Publicover J, et al. MR-guided prostate biopsy for planning of focal salvage after radiation therapy. Radiology. 2015;274:181-191.
3. Cochet A, Kanoun S, Humbert O, et al. Multimodality MRI and PET for restag-ing prostate cancer after biochemical failure of the treatment [in French]. Cancer Radiother. 2014;18:509-516.
4. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012;15:45-55.
5. Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S. Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol. 2011;80:e50-e56.
6. 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013;54:833-840.
7. Castellucci P, Fanti S. Prostate cancer: identifying sites of recurrence with choline-PET-CT imaging. Nat Rev Urol. 2015;12:134-135.
8. 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level, 0.5 ng/mL. Clin Nucl Med. 2013;38:e342-e345.
9. 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
10. 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085-1086.
11. 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41: 11-20.
12. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357-6362.
13. Rajasekaran AK. Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol. 2005;288:C975-C981.
14. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467-479.
15. 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
16. 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging. 2014;41:2222-2231.
17. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51-60.
18. Mottet N, Bellmunt J, Bolla M, et al. Reply to Stefano Fanti, Bernd Krause, Wolfgang Weber, et al's letter to the editor re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer [reply]. Eur Urol. 2011;60:e39-e41.
19. Swanson GP, Hussey MA, Tangen CM, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007;25:2225-2229.
20. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035-2041.
21. 11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:1106-1116.
22. 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. May 15, 201 [Epub ahead of print].
23. Haberkorn U, Afshar-Oromieh A, Giesel F, et al. PSMA ligands for diagnosis and therapy of prostate cancer [abstract]. Ann Oncol. 2015;26(suppl 2):ii33.